Home > Publications database > Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment. > print

001     179574
005     20240229145547.0
024 7 _ |a 10.1007/s00432-022-04016-y
|2 doi
024 7 _ |a pmid:35441345
|2 pmid
024 7 _ |a 0084-5353
|2 ISSN
024 7 _ |a 0171-5216
|2 ISSN
024 7 _ |a 0943-9382
|2 ISSN
024 7 _ |a 1432-1335
|2 ISSN
024 7 _ |a altmetric:126953349
|2 altmetric
037 _ _ |a DKFZ-2022-00752
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Apostolidis, Leonidas
|b 0
245 _ _ |a Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment.
260 _ _ |a Berlin
|c 2023
|b Springer
264 _ 1 |3 online
|2 Crossref
|b Springer Science and Business Media LLC
|c 2022-04-19
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1679485919_6245
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:D120# / 2023 Apr;149(4):1373-1382
520 _ _ |a Perioperative systemic treatment has significantly improved the outcome in locally advanced esophagogastric cancer. However, still the majority of patients relapse and die. Data on the optimal treatment after relapse are limited, and clinical and biological prognostic factors are lacking.Patients with a relapse after neoadjuvant/perioperative treatment and surgery for esophagogastric cancer were analyzed using a prospective database. Applied treatment regimens, clinical prognostic factors and biomarkers were analyzed.Of 246 patients 119 relapsed. Among patients with a relapse event, those with an early relapse (< 6 months) had an inferior overall survival (OS 6.3 vs. 13.8 months, p < 0.001) after relapse than those with a late relapse (> 6 months). OS after relapse was longer in patients with a microsatellite-unstable (MSI) tumor. Systemic treatment was initiated in 87 patients (73% of relapsed pat.); among those OS from the start of first-line treatment was inferior in patients with an early relapse with 6.9 vs. 10.0 months (p = 0.037). In 27 patients (23% of relapsed pat.), local therapy (irradiation or surgical intervention) was performed due to oligometastatic relapse, resulting in a prolonged OS in comparison to patients without local therapy (median OS 35.2 months vs. 7.8 months, p < 0.0001). Multivariate analysis confirmed the prognostic benefit of the MSI status and a local intervention.Patients relapsing after multimodal treatment have a heterogeneous prognosis depending on the relapse-free interval (if systemic treatment applied), extent of metastatic disease as well as MSI status. The benefit of additional local intervention after relapse should be addressed in a randomized trial.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
542 _ _ |i 2022-04-19
|2 Crossref
|u https://creativecommons.org/licenses/by/4.0
542 _ _ |i 2022-04-19
|2 Crossref
|u https://creativecommons.org/licenses/by/4.0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Esophagogastric cancer
|2 Other
650 _ 7 |a MSI
|2 Other
650 _ 7 |a Perioperative treatment
|2 Other
650 _ 7 |a Relapse
|2 Other
650 _ 7 |a Salvage treatment
|2 Other
700 1 _ |a Lang, Kristin
|b 1
700 1 _ |a Sisic, Leila
|b 2
700 1 _ |a Busch, Elena
|b 3
700 1 _ |a Ahadova, Aysel
|0 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000
|b 4
|u dkfz
700 1 _ |a Wullenkord, Ramona
|b 5
700 1 _ |a Nienhüser, Henrik
|b 6
700 1 _ |a Billeter, Adrian
|b 7
700 1 _ |a Müller-Stich, Beat
|b 8
700 1 _ |a Kloor, Matthias
|0 P:(DE-He78)3121b75683af3772ca9289d447889ed9
|b 9
700 1 _ |a Jaeger, Dirk
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Haag, Georg Martin
|0 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d
|b 11
|e Last author
|u dkfz
773 1 8 |a 10.1007/s00432-022-04016-y
|b Springer Science and Business Media LLC
|d 2022-04-19
|3 journal-article
|2 Crossref
|t Journal of Cancer Research and Clinical Oncology
|y 2022
|x 0171-5216
773 _ _ |a 10.1007/s00432-022-04016-y
|0 PERI:(DE-600)1459285-X
|n 4
|p 1373-1382
|t Journal of cancer research and clinical oncology
|v 149
|y 2023
|x 0171-5216
909 C O |p VDB
|o oai:inrepo02.dkfz.de:179574
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)07eef6d38a91f4642c810745c5bf5000
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)3121b75683af3772ca9289d447889ed9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)f54d0426f2215c539d3a7ae1b400b57d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CANCER RES CLIN : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-21
920 2 _ |0 I:(DE-He78)D120-20160331
|k D120
|l D120 Angewandte Tumor-Immunität
|x 0
920 1 _ |0 I:(DE-He78)F210-20160331
|k F210
|l KKE Angewandte Tumorbiologie
|x 0
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l D120 Angewandte Tumor-Immunität
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F210-20160331
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1016/S0140-6736(18)32557-1
|9 -- missing cx lookup --
|1 SE Al-Batran
|p 1948 -
|2 Crossref
|u Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1
|t Lancet
|v 393
|y 2019
999 C 5 |a 10.1097/SLA.0b013e318262a591
|9 -- missing cx lookup --
|1 K Becker
|p 1002 -
|2 Crossref
|u Becker K, Reim D, Novotny A, Zum Buschenfelde CM, Engel J, Friess H et al (2012) Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 256(6):1002–1007. https://doi.org/10.1097/SLA.0b013e318262a591
|t Ann Surg
|v 256
|y 2012
999 C 5 |a 10.1002/bjs.11290
|9 -- missing cx lookup --
|1 OS Bjerring
|p 1761 -
|2 Crossref
|u Bjerring OS, Fristrup CW, Pfeiffer P, Lundell L, Mortensen MB (2019) Phase II randomized clinical trial of endosonography and PET/CT versus clinical assessment only for follow-up after surgery for upper gastrointestinal cancer (EUFURO study). Br J Surg 106(13):1761–1768. https://doi.org/10.1002/bjs.11290
|t Br J Surg
|v 106
|y 2019
999 C 5 |a 10.3389/fonc.2021.669774
|1 E Busch
|9 -- missing cx lookup --
|2 Crossref
|u Busch E, Ahadova A, Kosmalla K, Bohaumilitzky L, Pfuderer PL, Ballhausen A et al (2021) Beta-2-microglobulin mutations are linked to a distinct metastatic pattern and a favorable outcome in microsatellite-unstable stage IV gastrointestinal cancers. Front Oncol 11:669774. https://doi.org/10.3389/fonc.2021.669774
|t Front Oncol
|v 11
|y 2021
999 C 5 |a 10.1056/NEJMoa055531
|9 -- missing cx lookup --
|1 D Cunningham
|p 11 -
|2 Crossref
|u Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. https://doi.org/10.1056/NEJMoa055531
|t N Engl J Med
|v 355
|y 2006
999 C 5 |a 10.1111/his.13491
|9 -- missing cx lookup --
|1 N Davarzani
|p 1180 -
|2 Crossref
|u Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D et al (2018) Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy—results from the MRC OE02 oesophageal cancer trial. Histopathology 72(7):1180–1188. https://doi.org/10.1111/his.13491
|t Histopathology
|v 72
|y 2018
999 C 5 |a 10.1200/JCO.2014.55.9070
|9 -- missing cx lookup --
|1 AR Davies
|p 2983 -
|2 Crossref
|u Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N et al (2014) Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol 32(27):2983–2990. https://doi.org/10.1200/JCO.2014.55.9070
|t J Clin Oncol
|v 32
|y 2014
999 C 5 |a 10.1016/S1470-2045(13)70549-7
|9 -- missing cx lookup --
|1 HE Ford
|p 78 -
|2 Crossref
|u Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15(1):78–86. https://doi.org/10.1016/S1470-2045(13)70549-7
|t Lancet Oncol
|v 15
|y 2014
999 C 5 |a 10.1007/s10120-016-0594-4
|9 -- missing cx lookup --
|1 R Giampieri
|p 156 -
|2 Crossref
|u Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L et al (2017) Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer 20(1):156–163. https://doi.org/10.1007/s10120-016-0594-4
|t Gastric Cancer
|v 20
|y 2017
999 C 5 |a 10.1200/JCO.2013.54.1011
|9 -- missing cx lookup --
|1 R Guimbaud
|p 3520 -
|2 Crossref
|u Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T et al (2014) Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32(31):3520–3526. https://doi.org/10.1200/JCO.2013.54.1011
|t J Clin Oncol
|v 32
|y 2014
999 C 5 |a 10.1002/ijc.32030
|9 -- missing cx lookup --
|1 GM Haag
|p 1697 -
|2 Crossref
|u Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S et al (2019) Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer 144(7):1697–1703. https://doi.org/10.1002/ijc.32030
|t Int J Cancer
|v 144
|y 2019
999 C 5 |a 10.1200/JCO.2012.48.5805
|9 -- missing cx lookup --
|1 S Hironaka
|p 4438 -
|2 Crossref
|u Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35):4438–4444. https://doi.org/10.1200/JCO.2012.48.5805
|t J Clin Oncol
|v 31
|y 2013
999 C 5 |a 10.1038/s41586-021-04161-3
|9 -- missing cx lookup --
|1 YY Janjigian
|p 727 -
|2 Crossref
|u Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O et al (2021) The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600(7890):727–730. https://doi.org/10.1038/s41586-021-04161-3
|t Nature
|v 600
|y 2021
999 C 5 |a 10.1016/S0140-6736(21)00797-2
|9 -- missing cx lookup --
|1 YY Janjigian
|p 27 -
|2 Crossref
|u Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2
|t Lancet
|v 398
|y 2021
999 C 5 |a 10.1158/1078-0432.CCR-20-2790
|9 -- missing cx lookup --
|1 M Lei
|p 3926 -
|2 Crossref
|u Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C et al (2021) Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab +/- ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin Cancer Res 27(14):3926–3935. https://doi.org/10.1158/1078-0432.CCR-20-2790
|t Clin Cancer Res
|v 27
|y 2021
999 C 5 |a 10.1016/j.ejso.2018.02.208
|9 -- missing cx lookup --
|1 K Polom
|p 626 -
|2 Crossref
|u Polom K, Boger C, Smyth E, Marrelli D, Behrens HM, Marano L et al (2018) Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. Eur J Surg Oncol 44(5):626–631. https://doi.org/10.1016/j.ejso.2018.02.208
|t Eur J Surg Oncol
|v 44
|y 2018
999 C 5 |a 10.1200/JCO.20.02755
|9 -- missing cx lookup --
|1 MA Shah
|p 990 -
|2 Crossref
|u Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA et al (2021) Phase III study to evaluate efficacy and safety of andecaliximab with mFOLFOX6 as first-line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1). J Clin Oncol 39(9):990–1000. https://doi.org/10.1200/JCO.20.02755
|t J Clin Oncol
|v 39
|y 2021
999 C 5 |a 10.1001/jamaoncol.2020.3370
|9 -- missing cx lookup --
|1 K Shitara
|p 1571 -
|2 Crossref
|u Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 6(10):1571–1580. https://doi.org/10.1001/jamaoncol.2020.3370
|t JAMA Oncol
|v 6
|y 2020
999 C 5 |a 10.1016/S0140-6736(18)31257-1
|9 -- missing cx lookup --
|1 K Shitara
|p 123 -
|2 Crossref
|u Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH et al (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 392(10142):123–133. https://doi.org/10.1016/S0140-6736(18)31257-1
|t Lancet
|v 392
|y 2018
999 C 5 |a 10.1200/JCO.2015.65.7692
|9 -- missing cx lookup --
|1 EC Smyth
|p 2721 -
|2 Crossref
|u Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A et al (2016) Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol 34(23):2721–2727. https://doi.org/10.1200/JCO.2015.65.7692
|t J Clin Oncol
|v 34
|y 2016
999 C 5 |a 10.1016/S0140-6736(21)01234-4
|9 -- missing cx lookup --
|1 JM Sun
|p 759 -
|2 Crossref
|u Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398(10302):759–71. https://doi.org/10.1016/S0140-6736(21)01234-4
|t Lancet
|v 398
|y 2021
999 C 5 |a 10.1016/j.ejca.2011.06.002
|9 -- missing cx lookup --
|1 PC Thuss-Patience
|p 2306 -
|2 Crossref
|u Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the arbeitsgemeinschaft internistische onkologie (AIO). Eur J Cancer 47(15):2306–2314. https://doi.org/10.1016/j.ejca.2011.06.002
|t Eur J Cancer
|v 47
|y 2011
999 C 5 |a 10.1158/1078-0432.CCR-20-2980
|9 -- missing cx lookup --
|1 ZA Wainberg
|p 1923 -
|2 Crossref
|u Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E et al (2021) Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score >/=10. Clin Cancer Res 27(7):1923–1931. https://doi.org/10.1158/1078-0432.CCR-20-2980
|t Clin Cancer Res
|v 27
|y 2021
999 C 5 |a 10.1016/S1470-2045(14)70420-6
|9 -- missing cx lookup --
|1 H Wilke
|p 1224 -
|2 Crossref
|u Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6
|t Lancet Oncol
|v 15
|y 2014
999 C 5 |a 10.1200/JCO.2010.33.0597
|9 -- missing cx lookup --
|1 M Ychou
|p 1715 -
|2 Crossref
|u Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715–1721. https://doi.org/10.1200/JCO.2010.33.0597
|t J Clin Oncol
|v 29
|y 2011

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21